Kurve Technology last week announced a new development and collaboration agreement with Seurat Therapeutics for migraine prevention in adults.
Mill Creek, Wash.-based Kurve Technology develops and markets intranasal drug delivery devices that transport liquid compounds from the nose to the brain to treat Alzheimer’s PTSD, multiple sclerosis and more.
“Both Seurat and Kurve are proud to be a part of making an effort to address the efficacy of migraine management,” CEO of Kurve Marc Giroux said in a press release. “We are pleased to see our business model of superior technology in a device that offers brand loyalty and market strength through the base unit and replaceable cartridges be accepted by Seurat and we foresee a bright future.”
Seurat Therapeutics is a biotech startup based in Chicago that is developing a nasal spray to stop and prevent migraines.
“When Seurat co-founders, Dr. Richard Kraig, Dr. Martin Sanders and Yuan Zhang contacted me regarding this therapy, it was a natural fit. As a company, Kurve has been interested in this area for some time and Seurat’s approach offers a real opportunity. It’s an exciting time with this agreement to be moving forward with our proprietary technology platform,” Giroux said.
